Splitsville: How Schedule III Is Creating Two Separate Cannabis Industries

When the DEA finalized cannabis rescheduling to Schedule III last year, the headlines were triumphant. Reform advocates called it historic. Industry trade groups issued glowing press releases. And it was, genuinely, a milestone — the first time in over fifty years that the federal government acknowledged cannabis had accepted medical uses and a lower potential for abuse than cocaine or fentanyl.

But the story that’s now unfolding is more complicated, and more consequential, than any of those victory laps suggested. Schedule III didn’t legalize cannabis. It didn’t make adult-use retail legal under federal law. What it did was draw a bright, binding line through the middle of an industry that had, for better or worse, been operating as a unified whole — and it drew that line in a way that will increasingly force operators, investors, and lawmakers to decide which side they’re on.

One Plant, Two Frameworks

The essential tension is this: Schedule III governs medical and research uses. For cannabis businesses operating in that lane — licensed medical dispensaries, FDA-registered research programs, pharmaceutical-track operations — rescheduling delivers real, substantive benefits. The crippling 280E tax provision no longer applies, because 280E only covers Schedule I and II substances. The cost of capital drops. Banking access opens up in ways that were simply not available before. The regulatory ceiling lifts, even if the walls still stand.

Adult-use cannabis is a different matter. Recreational sales remain federally illegal under the Controlled Substances Act, regardless of Schedule III status. No rescheduling action changes that. Adult-use operators — which represent the overwhelming majority of licensed cannabis revenue in states like California, Colorado, Illinois, and Michigan — still cannot access FDIC-insured banking without risk, still cannot deduct ordinary business expenses, and still operate in a legal gray zone that makes everything from payroll processors to insurance carriers skittish.

The result is something analysts are starting to call a bifurcated industry: a federally compliant medical tier, and a state-legal-but-federally-murky adult-use tier. They’re growing apart.

What the Banking Gap Actually Looks Like

It’s easy to talk about cannabis banking as an abstraction. It’s harder to absorb what it actually costs operators on the ground.

Cannabis Industry Journal recently laid out the math in blunt terms: for adult-use operators who can’t access conventional business loans or credit lines, the cost of capital isn’t just higher — it’s structurally punishing. Private equity terms that no conventional business would accept become the only option. Cash management creates compliance nightmares and theft exposure. Payroll complexity adds overhead that has nothing to do with growing or selling a better product.

The SAFE Banking Act has passed the House multiple times and stalled in the Senate. Under the current Congress, its trajectory is uncertain at best. Schedule III was supposed to ease some of this pressure. For the medical segment, it has. For adult-use, not so much.

This isn’t an accident of drafting. It reflects a deliberate policy choice — whether or not that choice was ever stated explicitly. The Biden administration’s rescheduling framework, inherited and allowed to proceed by the Trump administration, drew the Schedule III line precisely where FDA jurisdiction applies: medical and research contexts. Anything outside that framework remained untouched.

The Consumer Reality Doesn’t Respect the Legal Line

What makes this division politically awkward is that consumers don’t organize their lives around federal scheduling categories. They buy what’s available, use it for whatever they need, and don’t much care whether the regulatory framework calls it medical or recreational.

New NORML data published this week underscores just how fluid that line is in practice. Older Americans — a demographic not historically associated with cannabis use — are increasingly choosing cannabis over traditional pharmaceuticals. The reasons they give are telling: concerns about adverse effects, long-term health risks, and dependency associated with prescription medications. They view cannabis as a safer alternative. Whether they obtain it through a medical dispensary or an adult-use store often comes down to geography, access, and convenience rather than any meaningful therapeutic distinction.

Separate CDC data, also published this week, found that four percent of American adults frequently use cannabis to aid sleep — with rates nearly six percent among adults ages 18 to 35. That is not a medical-patient population in any narrow regulatory sense. That is just a lot of people who have found something that works for them and are using it.

The policy framework doesn’t know what to do with any of this. Schedule III was designed around a medical model that assumes doctors, pharmacies, and FDA-supervised supply chains. The actual cannabis market that tens of millions of Americans interact with daily looks nothing like that.

Where Congress Comes In — Or Doesn’t

The obvious legislative fix — federal adult-use legalization, or at minimum a descheduling framework that would harmonize the patchwork — remains stalled. The political math in the current Congress doesn’t favor it. House Republicans have shown limited appetite for anything that could be characterized as “legalizing drugs,” and the Senate’s procedural hurdles make even incremental reform difficult.

What some advocates are pushing instead is a narrower path: legislation that explicitly decouples banking access from scheduling status, allowing adult-use operators in compliant state markets to access FDIC-insured services without putting financial institutions at federal risk. The SAFER Banking Act, an updated version of SAFE, attempted this. It passed the Senate Banking Committee before the session ended. Whether it moves in this Congress is an open question.

The irony is that Schedule III, by concretely improving conditions for the medical segment, may have actually reduced political urgency around the adult-use banking problem. Why push for a comprehensive fix when half the industry now has a workable path? The answer — that the other half still doesn’t — isn’t as politically galvanizing as the unified industry pressure that preceded rescheduling.

The Bottom Line

Rescheduling to Schedule III was real progress. Nobody who has watched this issue for any length of time should dismiss it. But the post-rescheduling landscape is also a cleaner version of the same fundamental problem: federal law and state reality are still substantially out of alignment, and the businesses and consumers caught between them are still paying for that misalignment every day.

The cannabis industry isn’t going to merge back into a single legal category anytime soon. The question now is whether Congress and regulators treat the remaining adult-use gap as a problem to solve — or a situation to manage.

Based on what’s happened so far, the industry shouldn’t count on the former.

Ethan Vale covers federal cannabis legislation, DEA and FDA policy, Congress, and cannabis banking for CannabisInquirer.com.